Home Topics Cancer Celularity: Productizing Placental-Derived Stem Cells for Any Patient

Cells - medical background — [Source: Jezperklauzen / Getty Images]

Cancer
T Cells
CAR T-Cells
Cell Therapy
Drug Discovery
Financing
GEN Edge
Translational Medicine
Infectious Diseases

Celularity: Productizing Placental-Derived Stem Cells for Any Patient

Built on 20 years of research legacy and now public courtesy of a SPAC, this New Jersey-based clinical-stage biotechnology company is developing off-the-shelf allogeneic cell therapies.

By Jonathan D. Grinstein, PhD

April 28, 2021

[Source: Jezperklauzen / Getty Images]

Celularity is a clinical-stage biotechnology company focusing on the next evolution in cellular medicine by developing off-the-shelf placenta-derived allogeneic cell therapies, including genetically modified natural killer (NK) cells and T cells engineered with a chimeric antigen receptor (CAR-T cells) that target indications across cancer as well as infectious and degenerative diseases . . .